Cataplexy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Avadel, Axome Therapeutics

The cataplexy pipeline constitutes 3+ key companies continuously working towards developing 3+ cataplexy treatment therapies, according to DelveInsight.

DelveInsight's "Cataplexy - Pipeline Insight, 2025" offers a concise overview of the current pipeline landscape and future growth potential in cataplexy. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.

Request for a detailed cataplexy pipeline analysis report @ https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the cataplexy Pipeline Report:

DelveInsight's cataplexy pipeline analysis highlights a robust landscape, with 3+ active players developing 3+ pipeline drugs for the treatment of cataplexy across various stages of clinical development.
In December 2024, the FDA granted de novo classification and market authorization to ONWARD Medical's ARC-EX system. This non-invasive spinal cord stimulation device is the first of its kind approved to improve hand strength and sensation in individuals with chronic cataplexy. Clinical trials demonstrated that 72% of participants experienced enhanced hand function and sensory perception .​
In May 2024, the FDA approved Abbott's suite of Spinal Cord Stimulation (SCS) systems, including the Prodigy, Proclaim Plus, Proclaim XR, and Eterna systems. These implantable neurostimulators are designed to manage chronic pain in the torso, arms, and legs, offering relief for patients with intractable pain conditions .​
Key cataplexy companies such as Avadel, Axome Therapeutics, and others are evaluating new drugs for cataplexy to improve the treatment landscape.
Promising cataplexy pipeline therapies in various stages of development include FT218, AXS12, and others.

Cataplexy Overview

Cataplexy involves brief episodes of muscle weakness triggered by strong emotions, most often positive ones like laughter or excitement. These sudden attacks typically last from a few seconds to a few minutes and result from partial or complete paralysis of voluntary muscles. Despite the loss of muscle control, muscles responsible for eye movement and breathing remain unaffected. The condition is linked to the suppression of serotonergic and noradrenergic neural pathways, which leads to the temporary muscle paralysis observed during cataplectic episodes.

Uncover the latest breakthroughs in cataplexy therapeutics, download our report @ https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cataplexy Pipeline Analysis
The cataplexy pipeline insights report 2025 provides insights into:
Provides comprehensive insights into key companies developing therapies in the cataplexy Market.

Categorizes cataplexy therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging cataplexy drugs under development based on:

Stage of development

cataplexy Route of Administration

Target receptor

Monotherapy vs. combination therapy

cataplexy Mechanism of Action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

cataplexy Licensing Agreements

Funding and investment activities that support future advancements in the cataplexy market.

Get Full Insights into the cataplexy Pipeline and Future Market Trends - Download the Report Now: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cataplexy Emerging Drugs

FT218: Avadel

FT218 is a GABA B receptor agonist initially developed by Flamel Technologies. Currently, it is in Phase 3 clinical trials under the development of Avadel. The study began in June 2020 and is projected to conclude by June 2022, involving approximately 250 participants (ClinicalTrials.gov ID: NCT04451668).

AXS12: Axome Therapeutics

AXS12 (Reboxetine) is a Phase 2 investigational drug being developed by Axsome Therapeutics for the treatment of cataplexy. It functions as an adrenergic reuptake inhibitor.

Approximately three key companies are developing therapies for cataplexy. Among them, Avadel is the company with drug candidates in the most advanced stage, specifically Phase III.

Cataplexy Pipeline Therapeutic Assessment

Cataplexy Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Cataplexy By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cataplexy Assessment by Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Cataplexy Assessment by Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Download the cataplexy Sample Report for Key Insights on the cataplexy Treatment Market and Therapeutics: https://www.delveinsight.com/sample-request/cataplexy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Cataplexy Current Treatment Patterns
4. Cataplexy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cataplexy Late-Stage Products (Phase-III)
7. Cataplexy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cataplexy Discontinued Products
13. Cataplexy Product Profiles
14. Cataplexy Key Companies
15. Cataplexy Key Products
16. Dormant and Discontinued Products
17. Cataplexy Unmet Needs
18. Cataplexy Future Perspectives
19. Cataplexy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the cataplexy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/cataplexy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.